169 related articles for article (PubMed ID: 38040420)
1. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Katz MHG; Petroni GR; Bauer T; Reilley MJ; Wolpin BM; Stucky CC; Bekaii-Saab TS; Elias R; Merchant N; Dias Costa A; Lenehan P; Cardot-Ruffino V; Rodig S; Pfaff K; Dougan SK; Nowak JA; Varadhachary GR; Slingluff CL; Rahma O
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040420
[TBL] [Abstract][Full Text] [Related]
2. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
Ghaneh P; Palmer D; Cicconi S; Jackson R; Halloran CM; Rawcliffe C; Sripadam R; Mukherjee S; Soonawalla Z; Wadsley J; Al-Mukhtar A; Dickson E; Graham J; Jiao L; Wasan HS; Tait IS; Prachalias A; Ross P; Valle JW; O'Reilly DA; Al-Sarireh B; Gwynne S; Ahmed I; Connolly K; Yim KL; Cunningham D; Armstrong T; Archer C; Roberts K; Ma YT; Springfeld C; Tjaden C; Hackert T; Büchler MW; Neoptolemos JP;
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):157-168. PubMed ID: 36521500
[TBL] [Abstract][Full Text] [Related]
3. MZB1 in borderline resectable pancreatic cancer resected after neoadjuvant chemoradiotherapy.
Miyake K; Mori R; Homma Y; Matsuyama R; Okayama A; Murakami T; Hirano H; Endo I
J Surg Res; 2017 Dec; 220():391-401. PubMed ID: 29180208
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility complex class I-related chain A/B expression.
Murakami T; Homma Y; Matsuyama R; Mori R; Miyake K; Tanaka Y; Den K; Nagashima Y; Nakazawa M; Hiroshima Y; Ueda M; Tanaka K; Hoffman RM; Bouvet M; Endo I
J Surg Oncol; 2017 Sep; 116(3):416-426. PubMed ID: 28608409
[TBL] [Abstract][Full Text] [Related]
5. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy.
Michelakos T; Cai L; Villani V; Sabbatino F; Kontos F; Fernández-Del Castillo C; Yamada T; Neyaz A; Taylor MS; Deshpande V; Kurokawa T; Ting DT; Qadan M; Weekes CD; Allen JN; Clark JW; Hong TS; Ryan DP; Wo JY; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
J Natl Cancer Inst; 2021 Feb; 113(2):182-191. PubMed ID: 32497200
[TBL] [Abstract][Full Text] [Related]
6. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
[TBL] [Abstract][Full Text] [Related]
7. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
Homma Y; Taniguchi K; Murakami T; Nakagawa K; Nakazawa M; Matsuyama R; Mori R; Takeda K; Ueda M; Ichikawa Y; Tanaka K; Endo I
Ann Surg Oncol; 2014 Feb; 21(2):670-6. PubMed ID: 24310792
[TBL] [Abstract][Full Text] [Related]
8. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Xie H; Liu J; Yin J; Ogden JR; Mahipal A; McWilliams RR; Truty MJ; Bekaii-Saab TS; Petersen GM; Jatoi A; Hubbard JM; Ma WW
Oncologist; 2020 Nov; 25(11):e1681-e1690. PubMed ID: 32663355
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
[TBL] [Abstract][Full Text] [Related]
10. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma.
Zheng L; Ding D; Edil BH; Judkins C; Durham JN; Thomas DL; Bever KM; Mo G; Solt SE; Hoare JA; Bhattacharya R; Zhu Q; Osipov A; Onner B; Purtell KA; Cai H; Parkinson R; Hacker-Prietz A; Herman JM; Le DT; Azad NS; De Jesus-Acosta AMC; Blair AB; Kim V; Soares KC; Manos L; Cameron JL; Makary MA; Weiss MJ; Schulick RD; He J; Wolfgang CL; Thompson ED; Anders RA; Sugar E; Jaffee EM; Laheru DA
Clin Cancer Res; 2021 Mar; 27(5):1278-1286. PubMed ID: 33277370
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
12. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.
Kiryu S; Ito Z; Suka M; Bito T; Kan S; Uchiyama K; Saruta M; Hata T; Takano Y; Fujioka S; Misawa T; Yamauchi T; Yanagisawa H; Sato N; Ohkusa T; Sugiyama H; Koido S
BMC Cancer; 2021 Nov; 21(1):1197. PubMed ID: 34758773
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer.
Dias Costa A; Väyrynen SA; Chawla A; Zhang J; Väyrynen JP; Lau MC; Williams HL; Yuan C; Morales-Oyarvide V; Elganainy D; Singh H; Cleary JM; Perez K; Ng K; Freed-Pastor W; Mancias JD; Dougan SK; Wang J; Rubinson DA; Dunne RF; Kozak MM; Brais L; Reilly E; Clancy T; Linehan DC; Chang DT; Hezel AF; Koong AC; Aguirre AJ; Wolpin BM; Nowak JA
Clin Cancer Res; 2022 Dec; 28(23):5167-5179. PubMed ID: 36129461
[TBL] [Abstract][Full Text] [Related]
15. The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer.
Zwart ES; van Ee T; Doppenberg D; Farina A; Wilmink JW; Versteijne E; Busch OR; Besselink MG; Meijer LL; van Kooyk Y; Mebius RE; Kazemier G
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14731-14743. PubMed ID: 37587309
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
[TBL] [Abstract][Full Text] [Related]
17. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.
Bouchart C; Navez J; Borbath I; Geboes K; Vandamme T; Closset J; Moretti L; Demetter P; Paesmans M; Van Laethem JL
BMC Cancer; 2023 Sep; 23(1):891. PubMed ID: 37735634
[TBL] [Abstract][Full Text] [Related]
18. Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
Coveler AL; Pillarisetty VG; Koh WJ; Zhen DB; Park JO; King GG; Sham JG; Hannan LM; Mann GN; Baker KK; Redman MW; Swanson PE; Chiorean EG; Whiting SH
Pancreas; 2023 May; 52(5):e282-e287. PubMed ID: 37782886
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.
Overman M; Javle M; Davis RE; Vats P; Kumar-Sinha C; Xiao L; Mettu NB; Parra ER; Benson AB; Lopez CD; Munugalavadla V; Patel P; Tao L; Neelapu S; Maitra A
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114502
[TBL] [Abstract][Full Text] [Related]
20. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
Katz MH; Shi Q; Ahmad SA; Herman JM; Marsh Rde W; Collisson E; Schwartz L; Frankel W; Martin R; Conway W; Truty M; Kindler H; Lowy AM; Bekaii-Saab T; Philip P; Talamonti M; Cardin D; LoConte N; Shen P; Hoffman JP; Venook AP
JAMA Surg; 2016 Aug; 151(8):e161137. PubMed ID: 27275632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
